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In efforts to minimize the chronic administration of immunosuppression (IS) drugs in transplantation and
autoimmune disease, various cell-based tolerogenic therapies, including the use of regulatory or tolerogenic
dendritic cells (tolDC) have been developed. These DC-based therapies aim to harness the inherent
immunoregulatory potential of these professional antigen-presenting cells. In this short review, we describe both
the demonstrated tolerogenic properties, and current limitations of rapamycin-conditioned DC (RAPA-DC). RAPA-DC
are generated through inhibition of the integrative kinase mammalian target of rapamycin (mTOR) by the
immunosuppressive macrolide rapamycin during propagation of monocyte-derived DC. Consistent with the
characteristics of tolDC, murine RAPA-DC display resistance to phenotypic maturation induced by pro-inflammatory
stimuli; exhibit the ability to migrate to secondary lymphoid tissue (important for ‘cross-presentation’ of antigen to
T cells), and enrich for naturally-occurring CD4+ regulatory T cells. In rodent models, delivery of recipient-derived
RAPA-DC pulsed with donor antigen prior to organ transplantation can prolong allogeneic heart-graft survival
indefinitely, especially when combined with a short course of IS. These encouraging data support ongoing efforts
to develop RAPA-DC for clinical testing. When compared to murine RAPA-DC however, human RAPA-DC have
proven only partially resistant to maturation triggered by pro-inflammatory cytokines, and display heterogeneity in
their impact on effector T-cell expansion and function. In total, the evidence suggests the need for more in-depth
studies to better understand the mechanisms by which mTOR controls human DC function. These studies may
facilitate the development of RAPA-DC therapy alone or together with agents that preserve/enhance their
tolerogenic properties as clinical immunoregulatory vectors.
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Given their capacity to safely prevent and/or reverse
acute allograft rejection, immunosuppressive agents have
proven crucial to the successful clinical development of
organ transplantation. However, there are major limita-
tions associated with drug-based immunosuppression
(IS), including lack of antigen (Ag) specificity, failure to
support tolerance induction, deficiencies in the preven-
tion of late graft failure (chronic rejection), and signifi-
cant morbidity. Evaluation of novel, tolerance-promoting* Correspondence: thomsonaw@upmc.edu
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reproduction in any medium, provided the orprotocols, including cell-based therapies, such as the use
of tolerogenic dendritic cells (tolDC), is a dynamic area
of investigation and may provide a means to minimize
or even replace use of IS drugs [1]. In addition to redu-
cing the toxic burden of chronic IS, it is hoped that
these innovative approaches will prevent/reduce chronic
rejection, given the strong immunological involvement
in its etiology [2,3].
DC play critical roles in Ag presentation to naïve and
memory T cells and can either promote T-cell immunity
or support the induction of tolerance [4-6]. Experimen-
tal protocols are currently being developed with the goal
of harnessing the inherent tolerogenicity of DC to act as
‘negative cellular vaccines’, which can inhibit immune
responses in an alloAg-specific manner and promotel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Mouse vs. human immature RAPA-DC
Mouse Human
Phenotype [19,23,26,27]
MHC Class II # -
CD86/ CD40 ## #
B7-H1 # #
Migration [10,23,24]
CCR7 - "
Treg [21-23]
enrichment/induction/expansion " "
T cell apoptosis [10] ↑ ND
Function [15,19,20,23,27-29]
Endocytosis ## ND
MLR ## #
IL-12p70 # -
IL-10 # -
ND, not done; -, not changed.
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characteristically immature, express low surface MHC
molecules, a low ratio of co-stimulatory to co-inhibitory
signals, and an impaired ability to secrete T-helper-1
(Th1) cell-driving or inflammatory cytokines [2].
In particular, administration of tolDC presenting allo-
Ag promotes transplant survival through the induction of
T-cell hyporesponsiveness to allo-Ag, deletion of allor-
eactive T cells, or increased Treg incidence or functions
[7-10]. This knowledge has driven efforts to identify
mechanisms that underline the tolerogenic properties of
DC to promote transplant tolerance.
Various anti-inflammatory and immunosuppressive
agents have been used to generate tolDC in vitro, includ-
ing interleukin (IL)-10 and transforming growth factor-β
(TGF-β), cytotoxic T lymphocyte Ag-4 Ig (CTLA4-Ig),
prostaglandin E2 (PGE2), dexamethasone, and vitamin
D3 (vitD3), among others [11-13]. Of special interest to
our lab has been defining the molecular and functional
impact of the immunosuppressive pro-drug rapamycin
(RAPA) on DC.Phenotypic and functional characteristics of RAPA-DC
RAPA is a macrocyclic triene antibiotic with immuno-
suppressant properties, that was discovered in 1975 as a
product of the bacterium Streptomyces hygroscopicus in
a soil sample from Rapa Nui (Easter Island) [14]. This
immunosuppressant inhibits the mammalian target of
rapamycin (mTOR), a highly conserved serine/threonine
kinase that controls cellular responses to environmental
cues [15-17]. In mouse models, RAPA has a profound
impact on DC in vitro, impairing their maturation fol-
lowing exposure to Toll-like receptor (TLR) ligands and
suppressing their T-cell allostimulatory function [11,18-22]
(Table 1). RAPA has been reported to have unique
tolerance-promoting and Treg facilitating/sparing prop-
erties in small animal models of organ transplantation
[23,24]. We [10,25] and others [7,21,26,27] have shown
that when donor-derived, RAPA-conditioned DC
(RAPA-DC) or recipient-derived RAPA-DC pulsed with
donor allo-Ag are administered to recipients prior to
transplantation, donor graft survival is prolonged indef-
initely, especially when combined with a short course of
low dose IS, such as RAPA, cyclosporine, or FK506
(Table 2). Taner et al. have shown, in the mouse model,
prolongation of heart allograft survival when recipient-
derived RAPA-DC pulsed with allo-Ag were given i.v.
prior transplantation. Such results were improved with
short-term administration of subtherapeutic dose FK506,
which alone did not prolong graft survival or repeated
infusion of RAPA-DC pulsed with allo-Ag (x3; days −10,
-3, and 0) [10]. Turnquist et al. have also shown long-
term heart allograft survival, after a single i.v. dose ofrecipient-derived RAPA-DC pulsed with alloAg (day −7)
followed by a short-term course of low-dose RAPA [25].
When rodent and human DC are generated in
clinically-relevant concentrations of RAPA, they are
phenotypically immature, with low levels of cell surface
T-cell co-stimulatory molecules (CD86, CD40); however,
only murine RAPA-DC maintain their immature pheno-
type when exposed to inflammatory stimuli, such as bac-
terial lipopolysaccharide (LPS) [11,25]. Also, mouse and
human RAPA-DC exhibit a paradoxical decrease in cell
surface expression of B7-H1 (also known as pro-
grammed death ligand-1; PD-L1), a PD-1 ligand, which
contributes to the negative regulation of T lymphocyte
activation and promotes peripheral tolerance [13,28]
(Table 1).
Murine RAPA-DC induce hyporesponsiveness and/or
apoptosis of alloreactive T cells [10,11,18,22,25]. Like-
wise, human RAPA-DC are poorly stimulatory and in-
duce T-cell hyporesponsiveness [11]. Furthermore,
murine RAPA-DC retain the capacity to stimulate
mouse naturally-occurring Foxp3+ Treg, resulting in
an overall enrichment of this population relative to T
effector cells [25]. A similar capacity for promotion of
Foxp3+ cells in T-cell cultures has been reported for
human RAPA-DC [12] (Table 1).
Another important feature of murine RAPA-DC is
their unaltered chemokine receptor (CCR7) expression
and capacity for migration to CCL19/CCL21, and thus
to secondary lymphoid tissues [10,25,26]. Human
RAPA-DC have been reported to upregulate CCR7 ex-
pression and to display significantly augmented migra-
tion to CCL21 compared to control DC or other
ex vivo-generated human tolDC, such as those condi-
tioned with IL-10, dexamethasone, TGF-β, or vitamin
Table 2 Prolongation of allograft survival by RAPA-DC
Species Graft Source of DC IS agent in vivo Reference
Mouse Heart Bone marrow (BM) recipient-derived None 10
FK506 10
RAPA 23
Rat Limb BM recipient-derived ALS, CSA 18
Rat Vascularized skin BM recipient-derived ALS, CSA 7
Mouse Hematopoietic cells Autologous BM-derived (unpulsed) None 24
Mouse Pancreatic islets BM donor-derived None 25
ALS, anti-lymphocyte serum; CSA, cyclosporine A; IS, immunosuppression.
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expression/regulation and to migrate in vivo to second-
ary lymphoid tissue, while maintaining low expression of
CD86 and diminished T-cell allostimulatory capacity, has
important implications for their function as cellular ther-
apy (that is, ‘negative’ vaccines) for prevention of trans-
plant rejection [31] (Table 1).
RAPA-DC are also characterized by their unique cyto-
kine production profile upon LPS or pro-inflammatory
cocktail (IL-1β, tumor necrosis factor (TNF)-α, IL-6,
IFN-γ) stimulation. While IL-10 production is consist-
ently reduced in RAPA-DC [12,28], their production of
IL-12p70 may be affected differently. DC exposed to
RAPA in vivo exhibit decreased IL-12p70 production in
response to IL-4 stimulation; likewise, when DC are gen-
erated in culture with long exposure to RAPA, followed
by stimulation with agonistic anti-CD40 mAb, these
RAPA-DC display reduced IL-12p40 [18,25]. However,
we have described increased IL-12p70 production by
human monocyte-derived RAPA-DC after stimulation
with LPS [11,29] or pro-inflammatory cytokines
(Macedo et al., manuscript in preparation). Increased
production of IL-12p70 by RAPA-DC upon maturation
(LPS stimulation) has been associated with augmented
Th1/Th2-polarization of alloreactive CD4+ T cells [32]
and with Th1 responses upon pro-inflammatory cytokine
stimulation, towards IFN-γ production (Macedo et al.,
manuscript in preparation). Further definition of the
precise mechanisms by which mTOR controls and coor-
dinates cytokine production and expression of B7-H1 by
DC upon exposure to pro-inflammatory stimuli will be
important to fundamental understanding of DC immu-
nobiology and aid efforts to harness these promising
immunoregulatory vectors in transplant medicine and
autoimmune disease.
RAPA-DC from the bench to the clinic
The use of immunogenic or tolDC-based cell therapy in
the clinic has been reported by groups working in differ-
ent medical fields (cancer, HIV infection, and auto-
immune diseases) with positive outcomes in terms of its
feasibility and safety [33-36]. One aspect of tolDC-basedcell therapy in organ transplantation involves the use of
donor-derived tolDC in an effort to improve graft sur-
vival; however, such protocols can only be applied in a
live-donor setting since the in-vitro generation of tolDC
takes 5 to 7 days, precluding use of tolDC generated
from deceased donors. The generation of recipient-
derived DC loaded with donor allo-Ag (donor cell lysate,
apoptotic cells, or exosomes) is more advantageous,
since the generation of autologous RAPA-DC can be
performed at any time before transplantation and host
peripheral mononuclear cells (PBMC) can be cryopre-
served until time of tolDC generation/infusion. In
addition, Ag presentation via the indirect pathway is
thought to play an important role in the development
of chronic rejection, making recipient-derived DC, if
successful in regulating indirectly-alloreactive T cells, a
potentially ground-breaking tolerogenic cell therapy in
transplantation [37]. Immature DC such as RAPA-DC
can also regulate the expansion and differentiation of
Treg in vitro and in vivo, resulting in a ‘feedback’ regula-
tory loop [38,39]. On the current evidence, we cannot
say whether pre- or post-transplant administration of
tolDC, or whether autologous or donor-derived tolDCs,
will prove to be a superior treatment; however, it is our
personal opinion that alloantigen-pulsed recipient-
derived DCs represent a pragmatic approach and offer
certain theoretical advantages because of their indirect
presentation of alloantigen. It is an exciting prospect
that The ONE Study consortium will directly compare
different approaches to tolerogenic APC therapy in a
coherent clinical trial.
A means to obtain large numbers of monocytes is
through their enrichment from peripheral blood leuka-
pheresis products. The ElutraTM cell separation system
enriches monocytes untouched by antibodies or
microbeads within a closed system on the basis of size
and density [35,36]. Although not yet approved for clin-
ical use in many countries, as an alternative, the Clini-
MACSW cell separation system isolates monocytes by
positive selection using CD14 microbeads within a
closed system with a good purity [40,41]. Monocytes
generated using these techniques can be cultured in
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using an Aastrom Replicell system [12,35]. After 5 to
7 days of incubation, DC can be loaded with allo-Ag,
then evaluated for sterility, viability, recovery, and
phenotype; and either aliquoted for cryopreservation or
infused into the patient. We envisaged that the addition
of RAPA during human DC culture/expansion would
promote the tolerogenic features described above for
murine RAPA-DC (Table 3). However, exposure of
human RAPA-DC to maturation-inducing factors, such
as pro-inflammatory cytokines or TLR4 ligands in vitro
increased their production of IL-12p70, a Th1-inducing
cytokine that could augment pathogen-specific CD8+ T
cell responses and/ or promote alloimmunity [11,42]
and (Macedo et al., manuscript in preparation). As such,
methods to limit IL-12p70 production should be exam-
ined as part of any protocol for RAPA-DC generation
[11,43-45]. Recently, we have shown that increased IL-
12p70 production, by both mouse and human RAPA-
DC, following TLR4 ligation results from lost regulation
of glycogen synthase kinase 3 (GSK-3) [11]. As treat-
ment of RAPA-DC with GSK-3 inhibitors, such as lith-
ium chloride, ablated IL-12p70 production, RAPA-DC
treatment with GSK-3 inhibitors may be useful in limit-
ing any potential danger of increase Th1 immunity fol-
lowing RAPA-DC administration [11].
Another way to maintain RAPA-DC tolerogenicity fol-
lowing infusion of donor-derived or allo-Ag-pulsed
recipient-derived tolDC is the concomitant use of
costimulation-blocking agents, such as abatacept (CTLA4-
Ig) or belatacept (Lea 29Y), a first and second-generation
CTLA4-Ag, respectively, that block the B7-CD28 costi-
mulatory pathway [46,47]. Lu et al. [48] showed an
increase in experimental organ graft survival when anti-
CD40L mAb was administered in conjunction with
donor-derived myeloid DC to block the CD40/CD40L
pathway, which plays an important role in allogeneic
DC-T cell interactions in vivo. Later, Kirk et al. [49] and
Kenyon et al. [50] showed promising results in renal and
pancreatic islet transplantation, respectively, following
the administration of humanized CD154-specific mono-
clonal antibody in rhesus monkeys with acute rejection-Table 3 Generation of immature RAPA-DC
Research
Monocyte isolation CD14 microbeads (AutoMACSW or Clin
Culture conditions 10% fetal calf serum
(7 days) AIM-V media
1000 U/mL rhIL-4
1000 U/mL GM-CSF
10 ng/mL Rapamycin
Cell culture platesfree and prolongation of graft survival. However, in the
following year, Kawai et al. [51] documented a high inci-
dence of thromboembolic complications after the use of
monoclonal antibody against CD40L in monkeys. Never-
theless, further studies and pre-clinical evaluation of
CD40-CD40L pathway blockade in conjunction with
tolDC should be explored, including use of anti-CD40
prior to its application in patients.
A further clinically applicable question concerning
tolDC therapy is the route of DC administration, since it
could promote different outcomes. Giannoukakis et al.
[36] have reported injection of autologous NF-κB-
inhibited DC intradermally in the abdominal wall
overlying the anatomic location of the pancreas in type-
1 diabetic patients. As previously described by our
group, in the mouse model, systemic (intravenous) ad-
ministration of RAPA-DC was successful in significantly
prolonging alloAg-specific heart graft survival [10].
Macatangay et al. found no difference between subcuta-
neous and intravenous administration of autologous
monocyte-derived DC loaded with HIV-1 peptides deliv-
ered to subjects with chronic HIV-1 infection on anti-
retroviral therapy [52]. Since CCR7 and CD62L
expression on RAPA-DC is not affected by mTOR inhib-
ition, this may allow the cells to traffic normally to sec-
ondary lymphoid tissues, where their immunoregulatory
function is mediated [10,26,30].
How studies of human RAPA-DC relate to others’ work
In recent years, tolDC protocols have offered a potential
therapeutic tool in solid organ transplantation [1,2,53].
In order to compare different tolDC protocols, specific
characteristics of the tolDC need to be analyzed. These
include the phenotype, migration capability, cytokine
production (in both immature and mature states), the
ability to induce allogeneic T-cell proliferation, and the
expansion/induction of Treg. For the purpose of generat-
ing tolDC, these can be manipulated in vitro with differ-
ent immune modulators such as RAPA, dexamethasone,
IL-10, TGF-β, or vitD3 [1,2,11-13].
In humans, the majority of the tolDC generated using
the protocols mentioned above exhibit an immature toClinical
iMACSW) Elutriation or CD14 microbeads (CliniMACSW)
10% human serum
AIM-V media (c-GMP grade)
1000 U/mL rhIL-4 (c-GMP grade)
1000 U/mL GM-CSF (c-GMP grade)
10 ng/mL Rapamycin (c-GMP grade)
Cell culture plates or Aastrom Replicell system
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mediate expression of MHC II, CD86, CD83, and B7-
H1. RAPA-DC and TGF-β-DC have a higher migration
capability in response to CCL19 and CCL21 in vitro when
compared to IL-10- and vitD3-DC, with higher expression
of CCR7. Interestingly, all tolDC (dexamethasone-, IL-10-,
RAPA-, TGF-β-, and VitD3-DC) exhibit diminished pro-
duction of IL-23 when compared to mature untreated-
DC, whereas IL-10-DC and dexamethasone-DC were the
only population to show increased production of IL-10
[11-13]. However, the ability of tolDC to suppress T-cell
proliferation in humans is variable. IL-10-, TGF-β-, and
VitD3-DC can each suppress T-cell proliferation [11-13].
Contradictory effects of RAPA on DC in culture have been
reported. We have shown allo-PBMC hyporesponsiviness
in MLR when stimulated with RAPA-DC [11]. Naranjo-
Gomez et al. [12] have also shown RAPA-DC suppression
of T-cell proliferation in CFSE-MLR on the other hand,
Boks et al. [13] did not find RAPA-DC to be suppressive
in MLR and Haidinger et al. found an allostimulatory
effect of RAPA on DC (augmentation of IL-12, CD86,
IL-1β, and Ag presentation) [28]. Interestingly, Naranjo-
Gomez et al. have shown, in humans, as we reported pre-
viously in mice, that RAPA-DC are capable of significantly
sparing/expanding Treg, which suppress effector T-cell
allo-reactivity [11,12].
Other immunosuppressive cell types of myeloid origin,
such as macrophages [54], myeloid-derived suppressor
cells generated in the presence of PGE2 [55], and mes-
enchymal stem cells [56], have been introduced recently
to the transplant field, with suppressive properties that
may be suitable for clinical use. DC treated with differ-
ent cytokines and/or IS agents, macrophages, and mes-
enchymal stem cells mentioned above are being studied
currently by The ONE Study, a multinational clinical
assessment of immunomodulatory cell therapy in renal
transplantation [57-59].
Conclusions
In an effort to reduce the adverse side effects of chronic
IS after organ transplantation, tolDC protocols have
been used to generate ‘negative cellular vaccines’ with
potential therapeutic applicability. We have standardized
culture conditions to generate human monocyte-derived
RAPA-DC that exhibit tolerogenic characteristics, in-
cluding a more immature phenotype when compared to
control untreated DC. However, human RAPA-DC are
not fully resistant to maturation, but can induce Treg,
and have potential migratory capacity to secondary
lymphoid tissue (spleen and lymph nodes). Although
RAPA-DC exhibit unique immunoregulatory properties,
the immediate clinical implementation of RAPA-DC
is complicated by a dysregulation of pro- vs. anti-
inflammatory cytokine production, particularly IL-12p70and IL-10. However, methods to prevent increased IL-
12p70 production by RAPA-DC (such as use of lithium
chloride [11] or sanglifehrin A [60]) have been identified.
Likewise, IL-10 could be delivered with vaccination to
offset the reduced capacity of RAPA-DC to make IL-10.
Further insights into how mTOR regulates DC cytokine
production are critical for development of improved
‘negative’ and ‘positive’ cellular vaccines in general, and
to begin to translate these technologies to the bedside.
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